Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 18/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16932256 | 1.00 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL30194850 | 1.00 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL3487336 | 0.92 | DRD4 (0.64) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL26621783 | 0.92 | DRD4 (0.64) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL3443710 | 0.82 | DRD4 (0.61) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL9056881 | 0.82 | DRD4 (0.53) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL7368320 | 0.81 | DRD4 (0.59) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL13229950 | 0.81 | DRD4 (0.59) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL30917640 | 0.80 | DRD4 (0.54) | DRD4DRD2DRD3 | |
| SCHEMBL9581802 | 0.80 | DRD4 (0.66) | DRD4DRD2DRD3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325474-A | Spleen tyrosine kinase inhibitors | 尤尼奎斯特公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023193054-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | DRD4 4414/4885DRD2 4129/4885DRD3 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.